Sudo Biosciences Appoints Imran Babar, Ph.D., as Chief Business Officer

Autor:	Sudo Biosciences
Zdroj:	Business Wire (English). 10/10/2022.
Abstrakt:	Sudo Biosciences (“Sudo”), a biopharmaceutical company committed to designing and developing a broad pipeline of best-in-class precision TYK2 (tyrosine kinase 2) inhibitors, today announced the appointment of Imran Babar, Ph.D., as chief business officer. Dr. Babar is an accomplished industry leader with broad experience in healthcare strategy, life sciences finance, operations and business development. [ABSTRACT FROM PUBLISHER]
Databáze:	Regional Business News
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.